Instil Bio and ImmuneOnco will co-host an investor breakfast on May 31, 2025, discussing bispecific antibodies and clinical updates.
Quiver AI Summary
Instil Bio, Inc. and ImmuneOnco Biopharmaceuticals will host an investor and research analyst breakfast on May 31, 2025, in Chicago, focusing on the PD-(L)1xVEGF bispecific antibody landscape and recent clinical trial updates from both companies. The event will feature management from both firms and an immuno-oncology key opinion leader. Interested attendees should register by emailing Instil. ImmuneOnco specializes in developing biologics for cancer and other diseases, while Instil focuses on innovative therapies, including its lead asset, AXN-2510, targeting solid tumors.
Potential Positives
- Instil Bio is collaborating with ImmuneOnco to host an investor and research analyst breakfast, signaling a commitment to engage with stakeholders and share important insights on developments in the immuno-oncology field.
- The event will feature discussions on the evolving PD-(L)1xVEGF bispecific antibody landscape and recent clinical trial updates, showcasing Instil's proactive approach in communicating advancements in their pipeline.
- Instil's lead asset, AXN-2510, is a novel therapeutic targeting significant cancer treatment areas, highlighting their focus on innovative solutions within the biopharmaceutical industry.
- Hosting a key opinion leader in immuno-oncology indicates Instil's intention to align itself with thought leaders and enhance its credibility in the market.
Potential Negatives
- The press release does not provide specific details on any recent clinical trial results, which may raise concerns among investors about the current state and viability of Instil's lead asset, AXN-2510.
- There is a potential perception of a lack of transparency, as the company relies heavily on forward-looking statements without substantial information to back their future performance claims.
- Jointly hosting the event with ImmuneOnco, while a collaboration, may lead to questions about Instil's independent progress and competitive position in the bispecific antibody landscape.
FAQ
What is the event hosted by Instil Bio and ImmuneOnco?
Instil Bio and ImmuneOnco are hosting an investor and research analyst breakfast in Chicago to discuss bispecific antibodies and clinical updates.
When and where will the event take place?
The event will occur on Saturday, May 31, 2025, from 8:00 to 9:30 am CT, adjacent to the McCormick Convention Center in Chicago.
Who will be speaking at the event?
Management from Instil and ImmuneOnco, along with a key opinion leader in immuno-oncology, will speak at the breakfast.
How can I register for the investor breakfast?
Interested investors and analysts should email their contact information to [email protected] to reserve seating.
What is the focus of Instil Bio and ImmuneOnco?
Instil Bio focuses on developing innovative therapies for solid tumors, while ImmuneOnco targets biologics for cancers and autoimmune diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TIL Hedge Fund Activity
We have seen 20 institutional investors add shares of $TIL stock to their portfolio, and 33 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PERCEPTIVE ADVISORS LLC removed 345,545 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $6,596,454
- BOXER CAPITAL MANAGEMENT, LLC removed 275,375 shares (-77.5%) from their portfolio in Q1 2025, for an estimated $4,780,510
- BALYASNY ASSET MANAGEMENT L.P. added 255,691 shares (+414.9%) to their portfolio in Q1 2025, for an estimated $4,438,795
- MILLENNIUM MANAGEMENT LLC added 158,991 shares (+298.6%) to their portfolio in Q1 2025, for an estimated $2,760,083
- COMMODORE CAPITAL LP removed 150,929 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $2,881,234
- SUPERSTRING CAPITAL MANAGEMENT LP removed 148,017 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $2,569,575
- INVESCO LTD. removed 145,118 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $2,770,302
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
DALLAS and SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced that they will jointly host an investor and research analyst breakfast in Chicago, Illinois on Saturday, May 31, 2025 at 8:00 to 9:30 am CT adjacent to the McCormick Convention Center.
Instil and ImmuneOnco management, along with a key opinion leader in the field of immuno-oncology, will discuss the evolving PD-(L)1xVEGF bispecific antibody landscape and recent clinical trial updates from Instil and ImmuneOnco.
Investors and analysts interested in attending should register by emailing their contact information to reserve seating to [email protected] .
About ImmuneOnco
ImmuneOnco is a clinical-stage biotech company focused on discovery and development of biologics to treat cancers, autoimmune diseases and metabolic diseases. With 10+ assets all originated in-house and the most advanced asset in phase III right now, ImmuneOnco is pursuing innovative therapies to improve patients’ health. For more information visit
www.immuneonco.com
.
About Instil Bio
Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Instil's lead asset, AXN-2510, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumors. For more information, visit
www.instilbio.com
.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law.
Contacts:
Investor Relations:
1-972-499-3350
[email protected]
www.instilbio.com
